Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction
80% of participants were biologically confirmed abstinent from smoking at six months — a remarkably high rate compared with conventional cessation therapies, though in a tiny uncontrolled sample.
- Institution
- Johns Hopkins University
- Design
- Open-label pilot study
- Sample size
- 15 participants
- Intervention
- Psilocybin sessions embedded in a cognitive-behavioral smoking-cessation program
- Year
- 2014
- Condition
- Tobacco addiction
Very small, open-label, no control group, and combined with intensive behavioral therapy — the drug's specific contribution cannot be isolated.
A small but widely discussed pilot suggesting psilocybin might help with smoking cessation. The striking abstinence rate generated enthusiasm, but the uncontrolled design means it remains a promising lead rather than evidence.
Summary written by MMI Editorial for clarity. Always consult the primary source for full methodology and results. Confidence rating reflects our assessment of evidence strength.